Last updated on February 2015

Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT)


Brief description of study

Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT)

Detailed Study Description

RESTARRT is a clinical research study that is testing whether a combination of several medications can reset the immune system and help it accept a new kidney without the need for life-long immunosuppression.

The medications used in RESTARRT are anti-thymocyte globulin (ATG), rituximab, mycophenolate mofetil (MMF), tacrolimus and sirolimus. Participants in the RESTARRT study will receive these medications before, during, and after transplant. Standard immunosuppression drugs will initially be prescribed. Eligible participants will be asked to undergo a gradual reduction of their immunosuppressive medication with the goal of stopping these drugs permanently..

Clinical Study Identifier: TX140071

Find a site near you

Start Over

The Rogosin Institute - New York Presbyterian

Weill Cornell Medical Center<br /> 505 East 70th Street New York, NY USA
  Connect »

Massachussetts General Hospital

Transplant Center<br /> 55 Fruit Street Warren<br /> 735-C Boston, MA USA
  Connect »

The Rogosin Institute - New York Presbyterian

Weill Cornell Medical Center<br /> 505 East 70th Street New York, NY USA
  Connect »

University of Pennsylvania

Hospital of the University of Pennsylvania<br /> 3400 Spruce Street Philadelphia, PA USA
  Connect »

University of California, San Francisco

UCSF Medical Center<br /> 400 Parnassus Avenue San Francisco, CA USA
  Connect »

University of Maryland School of Medicine

Department of Surgery, Div. Transplantation<br /> 29 South Greene Street <br /> Suite 200 Baltimore, MD USA
  Connect »